Ipsen S.A. (IPSEY)
Data as of September 4, 2026 · Drug Manufacturers - Specialty & Generic
Stockbruh grade: Strong 4/5 metrics rated Sunny
What does Ipsen S.A. do?
Ipsen S.A. is a global biopharmaceutical company that specializes in oncology, neuroscience, rare diseases, and more 🌐. They offer a range of innovative drugs like Somatuline for tumors and Decapeptyl for advanced prostate cancer 💊. Based in Boulogne-Billancourt, France 🇫🇷, they're on a mission to improve lives and make a difference in healthcare 💪🏼.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ☀️ Strong | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ⛈️ Weak | Revenue & earnings trend |
| Earnings | ☀️ Strong | EPS vs analyst expectations |
| Cash & Debt | ☀️ Strong | Balance sheet strength |
| Price | $49.15 | Market Cap | — |
| Exchange | Other OTC | | |
Plain-English Analysis
What's it worth?
Based on 5-year performance trends, Ipsen S.A. has historically delivered strong returns. Sign up free for full valuation analysis including P/E, DCF estimates, and Stockbruh's plain-English take on whether this stock looks cheap or expensive right now.
Are they building the future?
Growth has been challenging recently. Revenue or earnings are showing weak trends. Sign up free to see the full picture including forward projections.
What's ahead?
Recent earnings have been strong, meeting or beating analyst expectations. Sign up free for earnings history, EPS trends, and what analysts are forecasting next.